◆英語タイトル:IDT Biologika GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014192
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
IDT Biologika GmbH (IDT Biologika), a subsidiary of Klocke Pharma-Service GmbH, is a manufacturer of vaccines and bio-pharmaceuticals products. It offers services which include integrated development and manufacturing services in four major areas of animal health, vaccines, pharmaceuticals and quality control. The company develops, manufactures and markets pharmaceutical products such as sterile, injectable and bio-engineered finished products. IDT Biologika handles manufacturing and quality control processes which include bulk active substances, sterile filling, packaging systems, cold chains, early development, small-batch production of samples and large-scale production. It has operational presence in the US and Germany. The company partners with biotechnology and pharmaceutical companies. IDT Biologika is headquartered in Dessau-Rosslau, Germany.
IDT Biologika GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
IDT Biologika GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
IDT Biologika Acquires Biopharmaceutical Development Center from Aeras 10
IDT Biologika Acquiers Animal Health Division from Riemser Pharma 11
Partnerships 12
CMC Biologics and IDT Biologika Enter into Agreement 12
Friedrich-Loeffler-Institut Enters into Collaboration Agreement with IDT Biologika 13
Acquisition 14
IDT Biologika to Acquire Gallant Custom Labs 14
IDT Biologika GmbH – Key Competitors 15
IDT Biologika GmbH – Key Employees 16
IDT Biologika GmbH – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
Nov 02, 2016: Process Development Laboratory opens in the ZENIT building in Magdeburg, Germany 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19
List of Tables
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Key Facts 2
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
IDT Biologika GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
IDT Biologika GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
IDT Biologika GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
IDT Biologika Acquires Biopharmaceutical Development Center from Aeras 10
IDT Biologika Acquiers Animal Health Division from Riemser Pharma 11
CMC Biologics and IDT Biologika Enter into Agreement 12
Friedrich-Loeffler-Institut Enters into Collaboration Agreement with IDT Biologika 13
IDT Biologika to Acquire Gallant Custom Labs 14
IDT Biologika GmbH, Key Competitors 15
IDT Biologika GmbH, Key Employees 16
IDT Biologika GmbH, Subsidiaries 17